	US 12,409,192 B2
	Traditional Chinese medicine composition and use thereof
Wei Xiao, Jiangsu (CN); Haibo Li, Jiangsu (CN); Guiping Li, Jiangsu (CN); Tuanjie Wang, Jiangsu (CN); Shasha Gu, Jiangsu (CN); Xu Li, Jiangsu (CN); Quanchang Zhang, Jiangsu (CN); Liang Cao, Jiangsu (CN); Wenjun Liu, Jiangsu (CN); Chenfeng Zhang, Jiangsu (CN); and Zhenzhong Wang, Jiangsu (CN)
Assigned to JIANGSU KANION PHARMACEUTICAL CO., LTD, Jiangsu (CN)
Appl. No. 18/715,154
Filed by JIANGSU KANION PHARMACEUTICAL CO., LTD, Jiangsu (CN)
PCT Filed Sep. 13, 2022, PCT No. PCT/CN2022/118405 § 371(c)(1), (2) Date May 31, 2024, PCT Pub. No. WO2023/098224, PCT Pub. Date Jun. 8, 2023.
Claims priority of application No. 202111467244.7 (CN), filed on Dec. 2, 2021.
Prior Publication US 2025/0017978 A1, Jan. 16, 2025
Int. Cl. A61K 36/00 (2006.01); A61K 33/06 (2006.01); A61K 35/32 (2015.01); A61K 35/413 (2015.01); A61K 36/484 (2006.01); A61K 36/539 (2006.01); A61K 36/708 (2006.01); A61K 36/8966 (2006.01); A61P 11/14 (2006.01); A61P 29/00 (2006.01); A61P 31/14 (2006.01)

CPC A61K 35/413 (2013.01) [A61K 33/06 (2013.01); A61K 35/32 (2013.01); A61K 36/484 (2013.01); A61K 36/539 (2013.01); A61K 36/708 (2013.01); A61K 36/8966 (2013.01); A61P 11/14 (2018.01); A61P 29/00 (2018.01); A61P 31/14 (2018.01)]

9 Claims

1. A medicine composition, containing active ingredients derived from the following medicines: Cornu caprae or Cornu saigae tataricae, Radix scutellariae Bulbus fritillariae ussuriensis, Radix glycyrrhizae, Radix et Rhizoma rhei, Gypsum fibrosum, Calculus bovis artifactus, and Lapis Chloriti, wherein the active ingredients comprise by weight: 1610.45-1901.21 parts by weight of amino acids, 120.27-167.01 parts by weight of gallic acid, 136.22-172.23 parts by weight of liquiritin, 21.23-37.12 parts by weight of liquiritigenin, 411.30-542.50 parts by weight of baicalin, 40.54-55.01 parts by weight of oroxyloside, 121.11-148.22 parts by weight of wogonoside, 287.88-333.32 parts by weight of glycyrrhizic acid, 12.87-24.11 parts by weight of chrysin-7-O-β-D-glucoronic acid, 50.11-55.21 parts by weight of aloe-emodin 8-O-β-D-glucopyranoside, 30.71-38.56 parts by weight of chrysophanol-1-O-β-D-glucopyranoside, 45.09-57.88 parts by weight of chrysophanol-8-O-β-D-glucopyranoside, 260.11-285.32 parts by weight of hyodeoxycholic acid, 151.11-191.03 parts by weight of cholic acid, wherein said medicine composition is adapted for the treatment of a condition selected from a fever, an inflammatory condition, a cough, or symptoms caused by a coronavirus infection.